Cargando…

Effective treatment of canine chronic cutaneous lupus erythematosus variants with oclacitinib: Seven cases

BACKGROUND: The treatment of canine chronic cutaneous lupus erythematosus (CCLE) variants generally requires immunosuppression, which often results in potentially severe adverse effects. Janus kinase inhibitors, like oclacitinib, might be a valuable treatment option due to their rapid inhibition of...

Descripción completa

Detalles Bibliográficos
Autores principales: Harvey, Richard G., Olivrī, Alla, Lima, Tatiana, Olivry, Thierry
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10092348/
https://www.ncbi.nlm.nih.gov/pubmed/36229964
http://dx.doi.org/10.1111/vde.13128
_version_ 1785023323732705280
author Harvey, Richard G.
Olivrī, Alla
Lima, Tatiana
Olivry, Thierry
author_facet Harvey, Richard G.
Olivrī, Alla
Lima, Tatiana
Olivry, Thierry
author_sort Harvey, Richard G.
collection PubMed
description BACKGROUND: The treatment of canine chronic cutaneous lupus erythematosus (CCLE) variants generally requires immunosuppression, which often results in potentially severe adverse effects. Janus kinase inhibitors, like oclacitinib, might be a valuable treatment option due to their rapid inhibition of the action of interferons known to be relevant in the pathogenesis of CCLE. OBJECTIVES: To report the efficacy and safety of oral oclacitinib for the treatment of canine CCLE variants. ANIMALS: Seven dogs were diagnosed with CCLE based on clinical signs and compatible histopathological findings. MATERIALS AND METHODS: Oclacitinib was administered at the induction dosage of 0.45 mg/kg twice daily to 1.8 mg/kg once daily. The response to treatment was graded as ‘good’ when there was ≥50% lesion reduction, or as ‘complete remission’ if all active lesions had resolved. Complete blood counts were performed at variable intervals. RESULTS: A complete remission of all lesions was obtained in the dog with exfoliative cutaneous lupus erythematosus, both dogs with mucocutaneous lupus erythematosus and three of four dogs with facial discoid lupus erythematosus (FDLE); a good response was seen in the remaining dog with FDLE. The first visible improvement of signs was seen within 2‐to‐3 weeks, while the time to complete remission was around 2 months. Clinical adverse effects were not seen, and haematological parameters remained within the reference range. CONCLUSIONS AND CLINICAL RELEVANCE: Oclacitinib may be considered an effective treatment option for different variants of canine CCLE.
format Online
Article
Text
id pubmed-10092348
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-100923482023-04-13 Effective treatment of canine chronic cutaneous lupus erythematosus variants with oclacitinib: Seven cases Harvey, Richard G. Olivrī, Alla Lima, Tatiana Olivry, Thierry Vet Dermatol Auto‐immune and Immune‐Mediated Dermatoses BACKGROUND: The treatment of canine chronic cutaneous lupus erythematosus (CCLE) variants generally requires immunosuppression, which often results in potentially severe adverse effects. Janus kinase inhibitors, like oclacitinib, might be a valuable treatment option due to their rapid inhibition of the action of interferons known to be relevant in the pathogenesis of CCLE. OBJECTIVES: To report the efficacy and safety of oral oclacitinib for the treatment of canine CCLE variants. ANIMALS: Seven dogs were diagnosed with CCLE based on clinical signs and compatible histopathological findings. MATERIALS AND METHODS: Oclacitinib was administered at the induction dosage of 0.45 mg/kg twice daily to 1.8 mg/kg once daily. The response to treatment was graded as ‘good’ when there was ≥50% lesion reduction, or as ‘complete remission’ if all active lesions had resolved. Complete blood counts were performed at variable intervals. RESULTS: A complete remission of all lesions was obtained in the dog with exfoliative cutaneous lupus erythematosus, both dogs with mucocutaneous lupus erythematosus and three of four dogs with facial discoid lupus erythematosus (FDLE); a good response was seen in the remaining dog with FDLE. The first visible improvement of signs was seen within 2‐to‐3 weeks, while the time to complete remission was around 2 months. Clinical adverse effects were not seen, and haematological parameters remained within the reference range. CONCLUSIONS AND CLINICAL RELEVANCE: Oclacitinib may be considered an effective treatment option for different variants of canine CCLE. John Wiley and Sons Inc. 2022-10-13 2023-02 /pmc/articles/PMC10092348/ /pubmed/36229964 http://dx.doi.org/10.1111/vde.13128 Text en © 2022 The Authors. Veterinary Dermatology published by John Wiley & Sons Ltd on behalf of ESVD and ACVD. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Auto‐immune and Immune‐Mediated Dermatoses
Harvey, Richard G.
Olivrī, Alla
Lima, Tatiana
Olivry, Thierry
Effective treatment of canine chronic cutaneous lupus erythematosus variants with oclacitinib: Seven cases
title Effective treatment of canine chronic cutaneous lupus erythematosus variants with oclacitinib: Seven cases
title_full Effective treatment of canine chronic cutaneous lupus erythematosus variants with oclacitinib: Seven cases
title_fullStr Effective treatment of canine chronic cutaneous lupus erythematosus variants with oclacitinib: Seven cases
title_full_unstemmed Effective treatment of canine chronic cutaneous lupus erythematosus variants with oclacitinib: Seven cases
title_short Effective treatment of canine chronic cutaneous lupus erythematosus variants with oclacitinib: Seven cases
title_sort effective treatment of canine chronic cutaneous lupus erythematosus variants with oclacitinib: seven cases
topic Auto‐immune and Immune‐Mediated Dermatoses
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10092348/
https://www.ncbi.nlm.nih.gov/pubmed/36229964
http://dx.doi.org/10.1111/vde.13128
work_keys_str_mv AT harveyrichardg effectivetreatmentofcaninechroniccutaneouslupuserythematosusvariantswithoclacitinibsevencases
AT olivrialla effectivetreatmentofcaninechroniccutaneouslupuserythematosusvariantswithoclacitinibsevencases
AT limatatiana effectivetreatmentofcaninechroniccutaneouslupuserythematosusvariantswithoclacitinibsevencases
AT olivrythierry effectivetreatmentofcaninechroniccutaneouslupuserythematosusvariantswithoclacitinibsevencases